Australia’s first-of-its-kind RNA Research and Pilot Manufacturing Facility is a step closer to reality, with the appointment of the main works contractor.
Following the approval of the project’s State Significant Development Application and competitive tender process, the construction contract has been awarded to Hindmarsh Construction. Construction is expected to commence in the coming months once the building contractor is established on site.
The new facility will be located in the Connect Macquarie Park Innovation District at Macquarie University and will be operated by Myeloid Therapeutics, a global therapeutics company.
The NSW Government has committed $96 million for the facility, with a further $119 million announced over 10 years for RNA research and development projects.
The project is being delivered by Health Infrastructure, on behalf of the Office of the NSW Chief Scientist & Engineer. The facility is expected to be operational in 2026.
MEDIA:
Jessica Jackson | Health Infrastructure | 0457 004 954